Structure Therapeutics Inc.

SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will participate in the Jefferies Global Healthcare Conference being held November 16-19, 2026 in London, UK. Jefferies Global Healthcare Conference Date: Tuesday, November 17Format: Fireside chat and 1x1 meetingsTime: 12:00 PM GMTLocation: London, UK The live and archived webcasts will be accessible from the company's website at  https://ir.structuretx.com/events-presentations/events  and replays will be available for at least 90 days.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension Date/Time: November 15, 2026, 2:30 p.m.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $22.10 and last traded at $22.31, with a volume of 1,434,790 shares changing hands. The stock had previously closed at $23.91. Wall Street Analyst Weigh In Several analysts recently